Evidence map›Paper›PMID 42811258›Full record

ReviewZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2026

[Regulatory mechanisms of post-translational modifications in inflammasome signaling: a review].

Chenyang He, Pinglong Xu, Shengduo Liu

Abstract readReviewEnglish Abstract
In one paragraph

Review in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Chenyang HeIntelligent Medicine Workshop, Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou 311200, China. morningsunh@163.com.
Pinglong XuLife Science Institute, Zhejiang University, Hangzhou 310058, China. xupl@zju.edu.cn.
Shengduo LiuIntelligent Medicine Workshop, Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou 311200, China. liushengduo@zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammasomes are central platforms of innate immunity that sense pathogenic and damage-associated signals and drive the maturation of proinflammatory cytokines as well as pyroptotic cell death. Their aberrant activation contributes to a wide range of pathological conditions, including inflammatory, autoimmune, metabolic, and neurological diseases. Recent studies have uncovered a dynamic regulatory network of post-translational modifications (PTMs) that governs the priming, assembly, activation, and degradation of inflammasome signaling. Ubiquitination and deubiquitination primarily control the stability, complex assembly, and degradation of inflammasome components. Phosphorylation and dephosphorylation regulate NLRP3 conformational switching, its interaction with NIMA-related kinase 7, and ASC speck formation through kinase-phosphatase crosstalk, while also modulating NLRC4 and Pyrin inflammasome activation. Acetylation and deacetylation, SUMOylation and deSUMOylation affect inflammasome assembly, protein degradation, and pyroptotic execution in a site- or isoform-specific manner. Collectively, these PTM networks determine the maturation and release of IL-1β and IL-18, as well as the intensity of gasdermin D-mediated pyroptosis. This review summarizes the major types of PTMs, their regulatory mechanisms, and the disease-related advances involving key inflammasome components. It also discusses therapeutic strategies and translational challenges associated with targeting these modification networks, with the aim of providing a reference for mechanistic studies and precision interventions in inflammation-associated diseases.

Indexed as

InflammasomesProtein Processing, Post-TranslationalSignal TransductionAnimalsHumansImmunity, InnateNLR Family, Pyrin Domain-Containing 3 ProteinPhosphorylationUbiquitinationInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinInflammasomePost-translational modificationPyroptosisReviewTargeted therapy

Identifiers

PMID42811258
PMCPMC13652681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.